5,832 Shares in Teladoc, Inc. (TDOC) Purchased by Raymond James Financial Services Advisors Inc.
Raymond James Financial Services Advisors Inc. acquired a new position in Teladoc, Inc. (NYSE:TDOC) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 5,832 shares of the health services provider’s stock, valued at approximately $202,000.
Several other institutional investors have also recently modified their holdings of TDOC. UBS Asset Management Americas Inc. acquired a new stake in shares of Teladoc in the first quarter worth $271,000. Parametric Portfolio Associates LLC acquired a new stake in shares of Teladoc in the first quarter worth $1,134,000. American International Group Inc. lifted its stake in shares of Teladoc by 22.2% in the first quarter. American International Group Inc. now owns 14,575 shares of the health services provider’s stock worth $364,000 after buying an additional 2,644 shares during the last quarter. Teachers Advisors LLC lifted its stake in shares of Teladoc by 53.6% in the first quarter. Teachers Advisors LLC now owns 54,067 shares of the health services provider’s stock worth $1,352,000 after buying an additional 18,862 shares during the last quarter. Finally, TIAA CREF Investment Management LLC lifted its stake in shares of Teladoc by 57.6% in the first quarter. TIAA CREF Investment Management LLC now owns 95,302 shares of the health services provider’s stock worth $2,383,000 after buying an additional 34,833 shares during the last quarter.
Shares of Teladoc, Inc. (NYSE TDOC) opened at $29.40 on Tuesday. The company has a quick ratio of 5.08, a current ratio of 5.08 and a debt-to-equity ratio of 0.83. Teladoc, Inc. has a fifty-two week low of $15.65 and a fifty-two week high of $37.55.
Teladoc (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.30) by ($0.25). The business had revenue of $68.70 million during the quarter, compared to the consensus estimate of $67.53 million. Teladoc had a negative net margin of 39.61% and a negative return on equity of 21.59%. The company’s quarterly revenue was up 112.0% compared to the same quarter last year. During the same period last year, the firm earned ($0.33) EPS. sell-side analysts expect that Teladoc, Inc. will post -1.57 EPS for the current year.
In other news, VP Mark Hirschhorn sold 25,000 shares of the company’s stock in a transaction dated Friday, September 22nd. The shares were sold at an average price of $31.93, for a total value of $798,250.00. Following the sale, the vice president now owns 64,987 shares of the company’s stock, valued at approximately $2,075,034.91. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Jason N. Gorevic sold 20,000 shares of the company’s stock in a transaction dated Monday, October 2nd. The stock was sold at an average price of $33.47, for a total transaction of $669,400.00. The disclosure for this sale can be found here. Insiders sold a total of 135,000 shares of company stock worth $4,408,700 in the last three months. Insiders own 4.47% of the company’s stock.
A number of brokerages have recently weighed in on TDOC. Cantor Fitzgerald restated a “hold” rating and issued a $31.00 price objective on shares of Teladoc in a research note on Tuesday, September 26th. BidaskClub upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a research note on Wednesday, August 9th. Cowen and Company restated an “outperform” rating and issued a $39.00 price objective on shares of Teladoc in a research note on Saturday, September 30th. Robert W. Baird lowered shares of Teladoc from an “outperform” rating to a “neutral” rating and boosted their target price for the stock from $14.00 to $36.00 in a research report on Monday, September 18th. Finally, Zacks Investment Research raised shares of Teladoc from a “sell” rating to a “buy” rating and set a $38.00 target price on the stock in a research report on Wednesday, October 4th. Five equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average target price of $38.17.
TRADEMARK VIOLATION WARNING: “5,832 Shares in Teladoc, Inc. (TDOC) Purchased by Raymond James Financial Services Advisors Inc.” was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another site, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this report can be viewed at https://www.thecerbatgem.com/2017/11/14/5832-shares-in-teladoc-inc-tdoc-purchased-by-raymond-james-financial-services-advisors-inc.html.
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.
Want to see what other hedge funds are holding TDOC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teladoc, Inc. (NYSE:TDOC).
Receive News & Stock Ratings for Teladoc Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc. and related stocks with our FREE daily email newsletter.